Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Immune therapy and β-cell death in type 1 diabetes.

Lebastchi J, Deng S, Lebastchi AH, Beshar I, Gitelman S, Willi S, Gottlieb P, Akirav EM, Bluestone JA, Herold KC.

Diabetes. 2013 May;62(5):1676-80. doi: 10.2337/db12-1207. Epub 2013 Feb 19.

2.

Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.

Sherry N, Hagopian W, Ludvigsson J, Jain SM, Wahlen J, Ferry RJ Jr, Bode B, Aronoff S, Holland C, Carlin D, King KL, Wilder RL, Pillemer S, Bonvini E, Johnson S, Stein KE, Koenig S, Herold KC, Daifotis AG; Protégé Trial Investigators..

Lancet. 2011 Aug 6;378(9790):487-97. doi: 10.1016/S0140-6736(11)60931-8. Epub 2011 Jun 28.

3.

Characterization of residual β cell function in long-standing type 1 diabetes.

Sherr JL, Ghazi T, Wurtz A, Rink L, Herold KC.

Diabetes Metab Res Rev. 2014 Feb;30(2):154-62. doi: 10.1002/dmrr.2478.

PMID:
24115337
4.

Treatment of new onset type 1 diabetes with teplizumab: successes and pitfalls in development.

Vudattu NK, Herold KC.

Expert Opin Biol Ther. 2014 Mar;14(3):377-85. doi: 10.1517/14712598.2014.881797. Review.

PMID:
24517093
5.

Effect of heat shock protein peptide DiaPep277 on beta-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1: two prospective, randomized, double-blind phase II trials.

Schloot NC, Meierhoff G, Lengyel C, Vándorfi G, Takács J, Pánczél P, Barkai L, Madácsy L, Oroszlán T, Kovács P, Sütö G, Battelino T, Hosszufalusi N, Jermendy G.

Diabetes Metab Res Rev. 2007 May;23(4):276-85.

PMID:
17103487
6.

Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders.

Herold KC, Gitelman SE, Ehlers MR, Gottlieb PA, Greenbaum CJ, Hagopian W, Boyle KD, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, McNamara J, Bluestone JA; AbATE Study Team..

Diabetes. 2013 Nov;62(11):3766-74. doi: 10.2337/db13-0345. Epub 2013 Jul 8.

7.

Prevention versus intervention of type 1 diabetes.

Brooks-Worrell B, Palmer JP.

Clin Immunol. 2013 Dec;149(3):332-8. doi: 10.1016/j.clim.2013.05.018. Epub 2013 Jun 10. Review.

PMID:
23803322
8.

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.

Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G, Gorus F, Goldman M, Walter M, Candon S, Schandene L, Crenier L, De Block C, Seigneurin JM, De Pauw P, Pierard D, Weets I, Rebello P, Bird P, Berrie E, Frewin M, Waldmann H, Bach JF, Pipeleers D, Chatenoud L.

N Engl J Med. 2005 Jun 23;352(25):2598-608.

9.

Changes in T-cell subsets identify responders to FcR-nonbinding anti-CD3 mAb (teplizumab) in patients with type 1 diabetes.

Tooley JE, Vudattu N, Choi J, Cotsapas C, Devine L, Raddassi K, Ehlers MR, McNamara JG, Harris KM, Kanaparthi S, Phippard D, Herold KC.

Eur J Immunol. 2016 Jan;46(1):230-41. doi: 10.1002/eji.201545708. Epub 2015 Dec 14.

10.

Immunotherapy trials for type 1 diabetes: the contribution of George Eisenbarth.

Skyler JS, Pugliese A.

Diabetes Technol Ther. 2013 Jun;15 Suppl 2:S2-13-S2-20. doi: 10.1089/dia.2013.0107.

11.

Prolactin as an Adjunct for Type 1 Diabetes Immunotherapy.

Hyslop CM, Tsai S, Shrivastava V, Santamaria P, Huang C.

Endocrinology. 2016 Jan;157(1):150-65. doi: 10.1210/en.2015-1549. Epub 2015 Oct 29.

PMID:
26512750
12.

Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes.

Rother KI, Spain LM, Wesley RA, Digon BJ 3rd, Baron A, Chen K, Nelson P, Dosch HM, Palmer JP, Brooks-Worrell B, Ring M, Harlan DM.

Diabetes Care. 2009 Dec;32(12):2251-7. doi: 10.2337/dc09-0773. Epub 2009 Oct 6.

13.

Anti-CD3 clinical trials in type 1 diabetes mellitus.

Daifotis AG, Koenig S, Chatenoud L, Herold KC.

Clin Immunol. 2013 Dec;149(3):268-78. doi: 10.1016/j.clim.2013.05.001. Epub 2013 May 11. Review.

PMID:
23726024
14.

Teplizumab therapy for type 1 diabetes.

Masharani UB, Becker J.

Expert Opin Biol Ther. 2010 Mar;10(3):459-65. doi: 10.1517/14712591003598843. Review.

15.

β cell death and dysfunction during type 1 diabetes development in at-risk individuals.

Herold KC, Usmani-Brown S, Ghazi T, Lebastchi J, Beam CA, Bellin MD, Ledizet M, Sosenko JM, Krischer JP, Palmer JP; Type 1 Diabetes TrialNet Study Group..

J Clin Invest. 2015 Mar 2;125(3):1163-73. doi: 10.1172/JCI78142. Epub 2015 Feb 2.

16.

Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial.

Herold KC, Gitelman SE, Willi SM, Gottlieb PA, Waldron-Lynch F, Devine L, Sherr J, Rosenthal SM, Adi S, Jalaludin MY, Michels AW, Dziura J, Bluestone JA.

Diabetologia. 2013 Feb;56(2):391-400. doi: 10.1007/s00125-012-2753-4. Epub 2012 Oct 21.

17.

CD3 monoclonal antibodies: a first step towards operational immune tolerance in the clinic.

Chatenoud L, Waldmann H.

Rev Diabet Stud. 2012 Winter;9(4):372-81. doi: 10.1900/RDS.2012.9.372. Epub 2012 Dec 28. Review.

18.

Analysis of β-cell death in type 1 diabetes by droplet digital PCR.

Usmani-Brown S, Lebastchi J, Steck AK, Beam C, Herold KC, Ledizet M.

Endocrinology. 2014 Sep;155(9):3694-8. doi: 10.1210/en.2014-1150. Epub 2014 Jul 8.

19.

Preexisting insulin autoantibodies predict efficacy of otelixizumab in preserving residual β-cell function in recent-onset type 1 diabetes.

Demeester S, Keymeulen B, Kaufman L, Van Dalem A, Balti EV, Van de Velde U, Goubert P, Verhaeghen K, Davidson HW, Wenzlau JM, Weets I, Pipeleers DG, Gorus FK.

Diabetes Care. 2015 Apr;38(4):644-51. doi: 10.2337/dc14-1575. Epub 2015 Jan 12.

20.

C-peptide response and HLA genotypes in subjects with recent-onset type 1 diabetes after immunotherapy with DiaPep277: an exploratory study.

Buzzetti R, Cernea S, Petrone A, Capizzi M, Spoletini M, Zampetti S, Guglielmi C, Venditti C, Pozzilli P; DiaPep Trialists Group..

Diabetes. 2011 Nov;60(11):3067-72. doi: 10.2337/db10-0560. Epub 2011 Sep 6.

Supplemental Content

Support Center